Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Viral Spread in the Gut Microbiome Mapped at Single-Particle Resolution

Scientists at the Charlie Dunlop School of Biological Sciences at UC Irvine report that they have developed a powerful new tool, called Phollow, that lets scientists watch viral activity in the gut microbiome of living animals with unprecedented precision—down

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Scientists at the Charlie Dunlop School of Biological Sciences at UC Irvine report that they have developed a powerful new tool, called Phollow, that lets scientists watch viral activity in the gut microbiome of living animals with unprecedented precision—down to a single viral particle.

Led by Travis Wiles, PhD, assistant professor, the study, “Phollow reveals in situ phage transmission dynamics in the zebrafish gut microbiome at single-virion resolution,” was published in Nature Microbiology and offers a window into how these nanoscopic predators spread, replicate, and shape the microbial ecosystems inside our bodies. Understanding how phages behave could one day lead to revolutionary ways to fine-tune the microbiome for better health.

Key role for phages

For years, scientists have suspected that phages play a key role in keeping gut bacteria in balance by eliminating harmful microbes while enabling beneficial ones to thrive. But directly observing this process has been nearly impossible due to the small size and ephemeral activity of phages. Behold, the Phollow system.

“With Phollow, we are able to watch phage outbreaks for the first time within the gut microbiome of a living animal,” said Wiles, the study’s senior author. “Directly observing how phages replicate and spread in microbial communities has the potential to yield clues to harnessing them for microbiome engineering and improving health.”

To make these invisible players visible, the team used zebrafish. By tagging phages with fluorescent markers, researchers tracked their every move. They found that antibiotics can trigger sudden “viral blooms,” where phages rapidly multiply and spread, dramatically altering a zebrafish’s gut microbial landscape in just hours.

Role for the zebrafish

“Illuminating phages with fluorescent proteins was somewhat straightforward but only the first step,” explained postdoctoral scholar Liz Ortiz, PhD, the study’s first author. “The nanoscopic size and dynamic nature of phages made it challenging to know where and when to find them within macroscopic animal hosts. We were able to overcome this challenge using zebrafish, which are small and transparent and thus made it possible to follow phage virions across the entire body.”

What they saw surprised them. In some cases, viral particles didn’t just stay in the gut, they appeared in the liver and even the brain, raising intriguing questions about how these microbial agents might interact with the body far beyond the digestive system.

The implications of this work go far beyond basic science. As scientists explore how to design personalized probiotics and develop phage therapies to combat drug-resistant bacteria, understanding how phages spread and interact with different hosts is essential. Phollow could become an essential tool for building that knowledge.

“The next major step is to understand how phage outbreaks shape health and disease,” said Wiles. “This will involve using Phollow to begin studying the immense diversity of uncharacterized phages that make up the intestinal virome.”

As the world begins to grapple with the promise and peril of manipulating the microbiome, tools like Phollow bring clarity to a once-invisible frontier, noted the research team. UC Irvine’s research looks like it points toward a future where targeted, phage-based therapies could enhance gut health, fight infections, and perhaps even prevent disease—one viral particle at a time.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →